Oramed Pharmaceuticals Inc (STU:OJU1)

€ 2.102 -0.075 (-3.45%) Market Cap: 87.25 Mil Enterprise Value: -53.80 Mil PE Ratio: 4.67 PB Ratio: 0.55 GF Score: 53/100

Oramed Pharmaceuticals Inc at Issuer Direct Planet MicroCap Showcase (Virtual) Transcript
Dec 07, 2022
Oramed Pharmaceuticals Inc NASH Data and KOL Webinar Transcript
Nov 17, 2022
Oramed Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
Oramed Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Aug 10, 2022
Genomma Lab Internacional SAB de CV & Oramed Pharmaceuticals Inc & Oravax Medical Inc Joint Venture Press Conference Transcript
Nov 18, 2021
Oramed Pharmaceuticals Inc The Journey of Oral Insulin: The Oramed Story Transcript
Nov 01, 2020

Oramed Pharmaceuticals Inc NASH Data and KOL Webinar Transcript

Nov 17, 2022 / 04:00PM GMT

Release Date Price: €7.83 (-8.51%)

Transcript 8-K10-Q

Operator

Ladies and gentlemen, thank you for standing by. Our conference will begin shortly.

Josh Hexter

Oramed Pharmaceuticals Inc. - COO & Chief Business Officer

Good morning and welcome to Oramed Pharmaceuticals Phase 2 NASH clinical data and KOL event. Today's webinar may contain forward-looking statements. Various remarks about the company's future expectations and plans constitute forward-looking statements. Actual results may differ from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's annual reports and other SEC filings available on the company's website. Please note that the remarks on today's call will be accompanied by a slide deck which is available in the events and presentations section of the company's website. The company will also be hosting a question-and-answer session at the conclusion of the prepared remarks. Today's event is being recorded.

We are all very excited to discuss the newly released NASH data from the Phase 2 study of Oramed's oral

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.